The search led to platensimycin, a small molecule made by the bacterium Streptomyces platensis. That bug normally lives in soil in South Africa.
In the May 18 Nature, the researchers report that platensimycin promptly kills lab-dish colonies of staphylococcus and enterococcus bacteria that resist drugs such as vancomycin and methicillin. When the researchers continuously infused mice with the drug in a first test, it killed Staphylococcus aureus that wasn't drug resistant.
Platensimycin is structurally different from other antibiotics. Unlike most of those drugs, it binds to and neutralizes an enzyme called FabF, which bacteria use to make fatty acids. Platensimycin "preexisted in nature to get this job done," Brown says. "This was pretty good detective work at Merck." Fatty acids are essential for building and maintaining the membrane that lines the bacterial cell wall. FabF is different from the corresponding enzyme in mammals, suggesting that platensimycin won't inhibit fatty acid synthesis in people, says Charles O. Rock, a biochemist at St. Jude Children's Research Hospital in Memphis, Tenn. This is the fourth natural compound-and by far the most potent-found to target FabF, Rock notes. "Nature is telling us again and again that if you want to go after bacteria, go after this enzyme," he says.
"If we look long enough and hard enough, we'll find these [fatty acid] inhibitors," says Steven J. Projan, a microbiologist at Wyeth Pharmaceuticals in Cambridge, Mass. But he cautions that the Merck team found it necessary to continuously infuse the drug in the mouse tests. That suggests that platensimycin might be metabolized too quickly in people to make a good drug candidate. Still, the study shows that derailing fatty acid synthesis can kill bacteria, Projan says.
The new finding "just goes to show you how marvelously clever nature is at blocking enzyme activity," says Brown.
Despite the heady results, the Merck scientists had no comment on whether the company would pursue further development of platensimycin.
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Antibiotic faces uncertain future
It can kill superbugs -but may never get used. Platensimycin has a novel chemical structure and works differently from other commercially available antibiotics by crippling FabF, a bacterial enzyme involved in manufacturing fatty acids. It thus stops bacteria from making the fatty cell membranes they need to grow. Two commercially available antibiotics, triclosan and isoniazid, target another enzyme involved in fatty-acid synthesis, but these do not kill the same array of bacteria.
An antibiotic has been discovered that kills the deadly methicillin-resistant Staphylococcus aureus.
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The researchers at Merck Research Laboratories in Rahway, New Jersey, who discovered platensimycin, did so by reviving and tuning an established strategy. They searched for naturally existing compounds that microbes typically make to kill neighbouring bacteria. This technique originally yielded many potent antibiotics, but was abandoned by many drug companies as the rate of return diminished and has been replaced by chemical methods to generate novel synthetic molecules.
Traditionally, researchers have tested whether a tiny amount of chemical can kill off a circle of bacteria growing on a plate. But by first making the bacteria more vulnerable, the Merck researchers searched for natural products that might have been missed in such conventional assays. They engineered S. aureus bacteria to make less of the FabF enzyme than normal, using a snippet of RNA to block the production of this protein Platensimycin could stumble at one of many scientific, regulatory or financial hurdles. One concern is that it may be unstable in the body, because the research team had to infuse it continuously into mice to rid them of a S. aureus infection. The chemical might need extensive modification to make it more stable, and could prove useless if it has toxic side effects.
Testing antibiotics in clinical trials is also tough and expensive. This is partly because the US Food and Drug Administration (FDA) does not have clear guidelines for approving new antibiotics, says Frank Tally, chief scientific officer of Cubist Pharmaceuticals in Lexington, Massachusetts, which developed daptomycin. Even if platensimycin is approved for human use, it will probably meet the fate of its predecessors, as bacteria rapidly acquire resistance to it. "It might make it to the clinic and then fade because of drug resistance," Nathan says.
With such a daunting task ahead, some microbiologists fear there is little incentive for Merck to develop the drug. Not only is the process hugely expensive, but the potential market for a new antibiotic -which is often used sparingly and administered for only a week or two -is small. This has prompted many pharmaceutical giants to cut back their antibiotic research programmes in recent years.
Platensimycin's discovery highlights the fact that compounds are still waiting to be found.
The Merck researchers refuse to spell out their plans for platensimycin, although they hint that they are working on it. "We are still in the business of doing antibiotic research, and we wouldn't be if we didn't want to develop our own compounds," says Sheo Singh, another of Merck's lead researchers. But many workers still think that novel antibiotics remain the best tried and tested way to combat microbes. They say platensimycin's discovery highlights the fact that compounds are still waiting to be found. "With a paper like this, people might start to reinvest in this area," Tally says, as it shows that new molecules can be found in well-known sources. 
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